WHO releases first global guideline on GLP-1 therapies for obesity treatment Anshika Mishra4 Dec 2025 8:00 AM ISTObesity now affects over 1 billion people worldwide, driving millions of deaths and trillions in costs-yet new WHO guidance offers hope through GLP-1...
Novo Nordisk seeks USFDA approval for higher dose of Wegovy injection Ruchika Sharma28 Nov 2025 11:30 AM ISTPlainsboro: Novo Nordisk has announced the submission of a sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide...
Tradipitant may Reduce Semaglutide-Induced Nausea and Vomiting, reports research Dr. Kamal Kant Kohli21 Nov 2025 8:00 PM ISTIn a randomized trial of adults with obesity or overweight, Vanda Pharmaceuticals' investigational NK-1 receptor antagonist tradipitant significantly...
Semaglutide, tirzepatide, and dulaglutide have similar Gl safety profiles in clinical settings, suggests study Dr. Kamal Kant Kohli18 Nov 2025 9:15 AM ISTA new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients...
Obesity drugs improve heart health: Study shows additional benefits of semaglutide and tirzepatide Dr. Kamal Kant Kohli13 Nov 2025 8:15 PM ISTInjectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes. Researchers at the Technical...
Medical Bulletin 12/November/2025 Dr. Bhumika Maikhuri12 Nov 2025 4:00 PM ISTHere are the top medical news for the day:Targeted Vitamin D Therapy Cuts Risk of Repeat Heart Attack by Half: Study Finds A new study has reported...
Semaglutide and Tirzepatide Cut Heart Risks in Type 2 Diabetes: Study Finds Dr. Bhumika Maikhuri12 Nov 2025 8:30 AM ISTA new database study has found that the injectable weight-loss drugs semaglutide and tirzepatide significantly reduce the risk of serious ...
Mazdutide Shows Superior Efficacy Over Semaglutide in Type 2 Diabetes with Obesity: Study Dr. Kamal Kant Kohli5 Nov 2025 8:30 PM ISTResearchers have found in a new DREAMS-3 trial, that GLP-1/GCG dual receptor agonist mazdutide outperformed semaglutide in reducing HbA1c levels and...
GLP-1 Receptor Agonists Linked to Lower Risk of Early Macular Degeneration: Study Dr Riya Dave3 Nov 2025 8:00 AM ISTResearchers have identified in a new study that exposure to glucagon-like peptide-1 receptor agonists (GLP-1RAs), commonly used for weight management,...
Sun Pharma Gets CDSCO Panel Approval to Conduct Phase III Study of Oral Semaglutide Susmita Roy25 Oct 2025 4:13 PM ISTNew Delhi: Pharmaceutical major Sun Pharma Laboratories has got the go ahead from the Subject Expert Committee (SEC) functional under the Central...
Study confirms cardiovascular benefits of semaglutide beyond weight loss: LANCET Dr. Kamal Kant Kohli25 Oct 2025 8:30 AM ISTA new analysis of the SELECT trial-the largest and longest clinical trial to date examining the cardiovascular benefits of semaglutide (a medication...
CDSCO Panel Seeks More Toxicity Data from Macleods on Semaglutide Injection Pre-Filled Pens Susmita Roy23 Oct 2025 1:28 PM ISTNew Delhi: The Subject Expert Committee (SEC), functioning under the Central Drugs Standard Control Organization (CDSCO), has opined that Macleods...
